Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

NCT01533181 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

NIH

Sponsor class

Conditions

Recurrent Small Cell Lung Carcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Linsitinib
OTHER: Pharmacological Study
DRUG: Topotecan Hydrochloride

Sponsor

National Cancer Institute (NCI)